Related Experiment Video
Updated: Jun 6, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
How I treat essential thrombocythemia
Philip A Beer1, Wendy N Erber, Peter J Campbell
1Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
Blood
|November 26, 2010
Summary
Recent advances improve essential thrombocythemia (ET) diagnosis and treatment. Molecular insights refine diagnostic processes and clarify ET
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Essential thrombocythemia (ET) is a myeloproliferative neoplasm.
- Recent years have seen significant progress in understanding ET's molecular basis.
- Distinguishing ET from related neoplasms like polycythemia vera and primary myelofibrosis remains challenging.
Purpose of the Study:
- To review recent advances in the diagnosis and treatment of essential thrombocythemia.
- To integrate molecular and histologic findings into a practical diagnostic approach.
- To discuss current therapeutic strategies and areas of clinical controversy in ET management.
Main Methods:
- Review of recent molecular and histologic studies.
- Analysis of diagnostic controversies and phenotypic overlap with other myeloproliferative neoplasms.
- Overview of current treatment approaches, including risk stratification and cytoreductive therapy.
Main Results:
- Molecular insights have enhanced diagnostic capabilities for essential thrombocythemia.
- A streamlined diagnostic process incorporating new data is presented.
- Current treatment strategies address risk stratification and special patient populations.
Conclusions:
- Integration of molecular and histologic data improves ET diagnosis.
- Risk-stratified treatment approaches optimize patient outcomes.
- Ongoing research addresses diagnostic and therapeutic controversies in ET.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...